
A UK trial found that hybrid closed-loop (HCL) insulin therapy significantly improved blood sugar control in women with type 1 diabetes during the first 6 months postpartum. Compared to standard care, HCL users had higher time-in-range (72% vs. 54%) with no increased hypoglycemia risk. Findings support HCL as a safe, effective option for postpartum diabetes management.
Like
Save
Share